12/20
05:59 am
hura
TuHURA Biosciences (NASDAQ: HURA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
High
Report
TuHURA Biosciences (NASDAQ: HURA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
12/19
10:30 am
hura
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders
High
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders
12/19
08:10 am
hura
TuHURA Biosciences (NASDAQ: HURA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $11.00 price target on the stock.
Low
Report
TuHURA Biosciences (NASDAQ: HURA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $11.00 price target on the stock.
12/16
01:09 pm
hura
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders
Medium
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders
12/12
05:19 pm
hura
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA
Medium
Report
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA
12/12
11:58 am
hura
HURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders
Low
Report
HURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders
12/12
08:45 am
hura
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
Medium
Report
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
11/25
08:58 am
hura
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update [Yahoo! Finance]
High
Report
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update [Yahoo! Finance]
11/25
08:35 am
hura
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
High
Report
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
11/5
08:12 am
hura
TuHURA Biosciences (NASDAQ: HURA) is now covered by analysts at Maxim Group. They set a "buy" rating and a $15.00 price target on the stock.
Medium
Report
TuHURA Biosciences (NASDAQ: HURA) is now covered by analysts at Maxim Group. They set a "buy" rating and a $15.00 price target on the stock.
10/23
08:30 am
hura
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Low
Report
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
10/22
09:00 am
hura
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
Medium
Report
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
10/17
04:35 pm
hura
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics
High
Report
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics